AN IN VITRO SCREEN FOR ATYPICAL BETA-ADRENERGIC AGONISTS

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$50,000.00
Award Year:
1990
Program:
SBIR
Phase:
Phase I
Contract:
N/A
Agency Tracking Number:
13801
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
California Biotechnology Inc
2450 Bayshore Pkwy, Mountain View, CA, 94043
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
N/A
Principal Investigator
 R Tyler White
 (415) 966-1550
Business Contact
Phone: () -
Research Institution
N/A
Abstract
THE ULTIMATE GOAL OF THIS RESEARCH IS TO DEVELOP A THERAPY FOR OBESITY BASED UPON THE IDENTIFICATION OF NOVEL BETA-ADRENERGIC AGONISTS THAT ARE SELECTIVE STIMULATORS OF THERMOGENESIS IN HUMANS. ATYPICAL (NON-BETA1, BETA2) BETA-ADRENERGIC RECEPTORS (BETA-ARS) ARE THOUGHT TO MEDIATE SYMPATHETIC NERVOUS SYSTEM STIMULATION OF THERMOGENESIS. ATYPICAL BETA- AGONISTS HAVE BEEN SHOWN TO STIMULATE THERMOGENESIS AND PROMOTE WEIGHT LOSS IN ANIMAL MODELS AND IN HUMAN CLINICAL TRIALS, BUT DESPITE THEIR RELATIVE SELECTIVITY, INTERACTIONS WITH BETA1-AR AND BETA2-AR PRODUCE SIDE EFFECTS. IMPROVEMENTS IN AGONIST SELECTIVITY FOR STIMULATION OF THERMOGENESIS WOULD LEAD TO USEFUL THERAPEUTICS. THE SPECIFIC AIM OF THE PROPOSED RESEARCH IS TO ESTABLISH A SCREENING SYSTEM FOR SELECTIVE THERMOGENIC BETA-AGONISTS. DURING PHASE I, THE POLYMERASE CHAIN REACTION (PCR) AND MOLECULAR CLONING TECHNIQUES WILL BE EMPLOYED TO IDENTIFY AND ISOLATE GENES FOR ATYPICAL BETA-ARS EXPRESSED IN TISSUESTHAT ARE SITES FOR THERMOGENESIS IN HUMANS. DURING PHASE II, THE GENES FOR ATYPICAL BETA-ARS WILL BE INTRODUCED INTO CHINESE HAMSTER OVARY CELLS TO ESTABLISH A MATRIX OF CELL LINES EXPRESSING FUNCTIONAL ATYPICAL RECEPTORS, WHICH WILL THEN BE USED TO SCREEN POTENTIAL THERMOGENIC AGONISTS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government